MARKET

FGEN

FGEN

Fibrogen Inc
NASDAQ
8.59
+0.16
+1.84%
After Hours: 8.59 0 0.00% 13:10 12/24 EST
OPEN
8.42
PREV CLOSE
8.43
HIGH
8.59
LOW
8.38
VOLUME
7.21K
TURNOVER
--
52 WEEK HIGH
21.94
52 WEEK LOW
4.850
MARKET CAP
34.73M
P/E (TTM)
0.1610
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at FGEN last week (1215-1219)?
Weekly Report · 3d ago
Is FibroGen (NASDAQ:FGEN) A Risky Investment?
Simply Wall St · 12/16 10:28
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 12/15 21:06
FibroGen: FDA Grants Orphan Drug Designation To Roxadustat For MDS
NASDAQ · 12/15 12:33
FibroGen Wins FDA Orphan Drug Status for Blood Disorder Treatment Roxadustat
Benzinga · 12/15 12:10
FibroGen granted orphan drug designation for roxadustat in MDS
TipRanks · 12/15 12:05
FDA Grants Orphan Drug Designation to FibroGen's Roxadustat for Myelodysplastic Syndromes
Reuters · 12/15 12:00
FIBROGEN INC - TO FILE PHASE 3 PROTOCOL IN Q4 2025
Reuters · 12/15 12:00
More
About FGEN
FibroGen, Inc. is a biopharmaceutical company focused on the development of novel therapies at the frontiers of cancer biology and anemia. It is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. It is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).

Webull offers FibroGen Inc stock information, including NASDAQ: FGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FGEN stock methods without spending real money on the virtual paper trading platform.